Benzinga | Aug 13, 2020 04:09PM EDT

Myriad Genetics Q4 Adj. EPS $(0.31) Beats $(0.47) Estimate, Sales $93.20M Miss $93.85M Estimate

Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.47) by 34.04 percent. This is a 175.61 percent decrease over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $93.20 million which missed the analyst consensus estimate of $93.85 million by 0.69 percent. This is a 56.73 percent decrease over sales of $215.40 million the same period last year.